Avatrombopag

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Avatrombopag
Avatrombopag.svg
Clinical data
Trade namesDoptelet
AHFS/Drugs.comMonograph
Routes of
administration
By mouth
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC29H34Cl2N6O3S2
Molar mass649.65 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)

Avatrombopag is a medication that used for certain conditions that lead to thrombocytopenia (low platelets) such as thrombocytopenia associated with chronic liver disease in adult patients who are to undergo a planned medical or dental procedure. It was approved for medical use in the United States in 2018.[1]

References[edit]

  1. ^ [1]FDA approves new drug for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure